- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
Increasingly, the concept of leaky gut is being touted by alternative and holistic practitioners as being fundamentally important in many chronic illnesses. By Peter A. Lio and Karan Lal, MS-4 It is now well accepted that skin barrier dysfunction is implicated in a variety of important inflammatory skin diseases including acne, atopic dermatitis, and psoriasis.1 […]
February 11, 2016 – Late last month, NEA’s Board of Directors gathered together for the annual NEA Board retreat in San Francisco, California. This year’s retreat focused on both celebrating 2015 successes, and sharing a number of exciting 2016 initiatives that will advance NEA’s Roadmap strategic plan goals.
February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.
November 17, 2016 – This year, more than 450 people joined NEA on two successful Itching for a Cure (IFAC) Walks in Chicago, IL and Los Angeles, CA. Together, we raised nearly $120,000 to improve the quality of life for individuals with eczema through research, support, and education.
September 21 – The National Eczema Association (NEA) has awarded Dr. Aaron Drucker, Assistant Professor, Department of Dermatology at Brown University, with the NEA Burden of Disease Research Audit grant, the findings of which will help to raise the profile of eczema as a serious disease, to deliver stronger, more united messages to insurers, medical providers and policy-makers on behalf of the eczema community.
May 22, 2015 – “Eczema keeps me from doing things that other people enjoy all the time, like going to the beach, riding my bike, going for a walk, and enjoying being outside,” says 13-year-old eczema patient, Isaiah Dixon. But that didn’t stop Isaiah from testifying in March at a Food and Drug Administration (FDA) hearing in Silver Spring, MD, on behalf of the National Eczema Association.
March 31, 2015 – A ninth-century remedy for eye infections has been found to kill the modern-day superbug MRSA and disrupt naturally antibiotic-resistant biofilms in tests conducted by researchers.
March 10, 2015 – On March 9, 2015, NEA CEO Julie Block, 13-year old eczema patient Isaiah, 17-year old eczema patient Gracie, and their parents were present at an important Food and Drug Administrative (FDA) hearing regarding the unmet medical need for atopic dermatitis therapies in pediatrics.
March 5, 2015 – Check out this NPR piece on an important new study about how eczema affects the lives of people who have it by NEA Scientific Advisory Committee member Jonathan Silverberg, MD. Data from this study demonstrates the burden of living with eczema, which helps further the case for more eczema research.